Tag Archives: Livongo

Livongo Partners with Higi; Dario Hires New President and Head of NA

Two diabetes-related connected care news items have been observed. First, Livongo announced it has partnered with Higi to make Livongo for Diabetes and Livongo for Hypertension available at Higi’s “Smart Health Stations.” Additionally, Dario Health appointed Rick Anderson as the company’s new President and General Manager of North America. Below, FENIX provides thoughts and insights into the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Teplizumab Regulatory Update; Sanofi Partners with Biocorp; Livongo Preferred on ESI; Omnipod Horizon Pivotal Trial Initiated; Glooko Partners with Mellitus Health

A series of diabetes-related new items were observed today including an update on Provention Bio’s teplizumab, a new Sanofi/Biocorp connected pen partnership, Livongo’s preferred status on ESI, Insulet’s Omnipod Horizon pivotal study, and more. Below FENIX provides insights and context from each respective news item.

This content is for Read Less members only.
Register
Already a member? Log in here

Dexcom and Livongo Q3 ’19 Earnings Updates

Dexcom and Livongo hosted their Q3 ’19 earnings calls and provided updates to their respective businesses. Below, FENIX provides highlights and insights from the respective earnings calls.

This content is for Read Less members only.
Register
Already a member? Log in here

Abbott and Tandem partnership; Livongo partners with VSP Vision Care

Abbott and Tandem Diabetes Care announced plans to develop an integrated diabetes solution utilizing Abbott’s glucose monitoring sensors (Libre) and Tandem’s insulin delivery systems. Additionally, Livongo and VSP Vision Care announced a partnership to expand eye care outreach efforts to Livongo members with diabetes. Below, FENIX provides context and broader implications on these partnerships.

This content is for Read Less members only.
Register
Already a member? Log in here

Livongo Stock Plunges After First Post-IPO Earnings Release (Q2 ’19)

Livongo hosted its first earnings call following its July 2019 IPO. Senior management provided an overview of the company including its client and member growth prospects. Below, FENIX provides highlights and insights from the call including thoughts on why the Livongo stock plummeted following the company’s first earnings release.

This content is for Read Less members only.
Register
Already a member? Log in here

Livongo-Abbott Integration with Libre Pro

Livongo announced a partnership with Abbott to integrate the FreeStyle Libre Pro into the Livongo for Diabetes program. The integration with a professional (retrospective) CGM makes sense given Livongo’s focus on patient education and behavior-based treatment. Below, FENIX provides a unique perspective that the Abbott partnership could signal a limitation in Livongo’s diabetes solution.

This content is for Read Less members only.
Register
Already a member? Log in here

Livongo Acquires Digital Obesity Company

Livongo announced it has acquired Retrofit, a Chicago-based digital solutions company focusing on weight management and diabetes prevention. Livongo’s expansion into the obesity digital health market is the next logical step for the company as it seeks to provide a more holistic solution. Below, FENIX provides analysis of the Retrofit acquisition.

This content is for Read Less members only.
Register
Already a member? Log in here

Livongo partners with Cambia Health Solutions and raises $105M

Livongo announced a new $105M round of funding and a new strategic partnership. The new funding round brings the total capital raised by Livongo to $243.2M. The new strategic collaboration with Cambia Health Solutions will focus on improving personalized health care for patients with chronic conditions and brings on a new investor named Echo Health Ventures.

This content is for Read Less members only.
Register
Already a member? Log in here